Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (11416)	8/19/1999 5:33:00 PM
From: opalapril	Read Replies (2) \| Respond to of 17367

I'm not Cacaito but my take on the hu1124 announcement is, shall I say, mutedly optimistic. The press release has all the earmarks of something arranged since Monday night. Remember the last time? Xoma said they couldn't announce until all details had been worked out and the agreement signed. Then Genentech preempted them, leaving Xoma exposed and looking damned foolish. But suddenly today, it's okay to trumpet something agreed to in 'principle'? Looks like a sort of life ring; friendly compensation one might say for the earlier screw up. Nevertheless, I think it is really good news, only for a different reason. I doubt Genentech would have done this for Xoma unless there really had been a preexisting general understanding along the lines announced. I also doubt they would have done it for Xoma unless the relationship here is a lot more cosy than we have supposed. Reminds me of something analogous. What do the Norfolk Tide, Toledo Mud Hens, Portland Mavericks, and Xoma, Ltd. have in common?

To: Bluegreen who wrote (11416)	8/19/1999 10:37:00 PM
From: Cacaito	Respond to of 17367

Bluegreen, hu1124 news a good sign Genentech is interested in xoma. The hu1124 for inhibition of organ transplant rejection is a good product (many in the market, many in trials, IDECC work with xoma in the field?) Genentech will pick a good antigen to block, xoma will build the mab and the usual 25%/75% division. Unless Genentech has a new target (not the usual ones already in multiple products)dosing advantage, price advantage, and/or superior performance (like Genentech new SuperTpa) then they have a me too product in the market in 3 to 5 years. Check CVTX 55% up in the second day follow up after the phase III announcement (up 100% intraday). It would have been xoma, well maybe the big one is in october, I will miss it. Fellow ex investor (not ex fellow). xoma is presenting in San Francisco in september 99, is it about bpi? Viena conference is clearly about bpi in October? Is xoma the bloomberg bee?